Fernando M. A.
- Country
- Spain
- Department
- oncology
Research Overview
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- C4891002: A Phase 3, Randomized, Open-Label, Multicenter Study Of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib For The Treatment Of Participants With Estrogen Receptor Positive, HER2-Negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease (VERITAC-3)
- A Phase II Randomized, Double-Blind Study Comparing Fulvestrant and Palbociclib Versus Fulvestrant and Placebo in HR-Positive Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 183 of 424 partner sites.
Specializations
HER2-Positive Breast Cancer
The investigator specializes in treating HER2-positive breast cancer, with particular focus on early-stage disease management and hormone receptor-positive subtypes. Their research encompasses therapeutic approaches for patients who have completed neoadjuvant and adjuvant trastuzumab-based therapy.
- Early-stage HER2+ breast cancer
- Hormone receptor-positive disease
- Post-trastuzumab therapy management
Triple-Negative Breast Cancer
The investigator conducts research in advanced triple-negative breast cancer, exploring novel combination therapies. Their work includes evaluation of innovative treatment approaches in both early-stage and advanced disease settings.
- Advanced TNBC management
- Neoadjuvant treatment strategies
- Immunotherapy combinations
Metastatic Breast Cancer
The investigator focuses on treating hormone receptor-positive metastatic breast cancer, including HER2-low disease variants. Their expertise extends to managing patients with long-term endocrine therapy experience and those with de novo metastatic disease.
- HER2-low breast cancer
- Endocrine therapy resistance
- Novel therapeutic combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.